T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...

The Food and Drug Administration (FDA) is hitting some speed bumps in implementing the Trump campaign agenda, and the ...

Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...

Dr. Vinay Prasad’s rehiring was an unusual instance of a federal official targeted by the right-wing activist Laura Loomer ...

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to his post, according to the Department of Health and Human Services ...

Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...

WASHINGTON — Vinay Prasad is returning to the Food and Drug Administration to resume his role overseeing vaccine, gene ...

The Sarepta Missionary Baptist Church family invites the community to join them for the Annual Homecoming Service on Sunday, Aug. 10, at 11:45 a.m.

Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.